BEIJING–(BUSINESS WIRE)–On November 26, 2020, Beijing Handian Pharmaceutical held an expert seminar on anti-COVID-19 medicine “Honee Taishen Granule” in Ritan, Beijing.

At this meeting, the company invited a number of experts from the Chinese Academy of Sciences and the Chinese Academy of Medical Sciences to discuss the current research results of “Taishen Granules” and put forward their suggestions on the future research and development direction of this drug.

The company started a long-term anti-plague research program since Ebola outbreak in 2015, and Taishen Granule comes from a reserve formula of that program. This formula is derived from an ancient prescription against Taiyin cold-dampness and stagnation lung syndrome, which is consistent with symptoms of this COVID-19 epidemic according to traditional Chinese medicine theory. The company’s scientific

Read More At Article Source | Article Attribution